-
1
-
-
0029586398
-
Clinical pharmacokinetics of tacrolimus
-
Venkataramanan R, Swaminathan A, Prasad T, Jain A, Zuckerman S, Warty V et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 1995; 29: 404-430. (Pubitemid 26004179)
-
(1995)
Clinical Pharmacokinetics
, vol.29
, Issue.6
, pp. 404-430
-
-
Venkataramanan, R.1
Swaminathan, A.2
Prasad, T.3
Jain, A.4
Zuckerman, S.5
Warty, V.6
McMichael, J.7
Lever, J.8
Burckart, G.9
Starzl, T.10
-
2
-
-
3242772986
-
Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation
-
DOI 10.2165/00003088-200443100-00001
-
Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 2004; 43: 623-653. (Pubitemid 38981845)
-
(2004)
Clinical Pharmacokinetics
, vol.43
, Issue.10
, pp. 623-653
-
-
Staatz, C.E.1
Tett, S.E.2
-
3
-
-
0032773854
-
Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation
-
Jones DR, Gorski JC, Hamman MA, Mayhew BS, Rider S, Hall SD. Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation. J Pharmacol Exp Ther 1999; 290: 1116-1125. (Pubitemid 29400251)
-
(1999)
Journal of Pharmacology and Experimental Therapeutics
, vol.290
, Issue.3
, pp. 1116-1125
-
-
Jones, D.R.1
Gorski, J.C.2
Hamman, M.A.3
Mayhew, B.S.4
Rider, S.5
Hall, S.D.6
-
4
-
-
0033032643
-
Diltiazem increases tacrolimus concentrations
-
DOI 10.1345/aph.18356
-
Hebert MF, Lam AY. Diltiazem increases tacrolimus concentrations. Ann Pharmacother 1999; 33: 680-682. (Pubitemid 29309723)
-
(1999)
Annals of Pharmacotherapy
, vol.33
, Issue.6
, pp. 680-682
-
-
Hebert, M.F.1
Lam, A.Y.2
-
5
-
-
0036290197
-
Pharmacokinetic interaction between tacrolimus and diltiazem: Dose-response relationship in kidney and liver transplant recipients
-
Jones TE, Morris RG. Pharmacokinetic interaction between tacrolimus and diltiazem: dose-response relationship in kidney and liver transplant recipients. Clin Pharmacokinet 2002; 41: 381-388. (Pubitemid 34713091)
-
(2002)
Clinical Pharmacokinetics
, vol.41
, Issue.5
, pp. 381-388
-
-
Jones, T.E.1
Morris, R.G.2
-
6
-
-
53549126614
-
Effects of CYP3A5 and MDR1 single nucleotide polymorphisms on drug interactions between tacrolimus and fluconazole in renal allograft recipients
-
Kuypers DR, de Jonge H, Naesens M, Vanrenterghem Y. Effects of CYP3A5 and MDR1 single nucleotide polymorphisms on drug interactions between tacrolimus and fluconazole in renal allograft recipients. Pharmacogenet Genomics 2008; 18: 861-868.
-
(2008)
Pharmacogenet Genomics
, vol.18
, pp. 861-868
-
-
Kuypers, D.R.1
De Jonge, H.2
Naesens, M.3
Vanrenterghem, Y.4
-
7
-
-
56149107690
-
Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism
-
Kalliokoski A, Backman JT, Kurkinen KJ, Neuvonen PJ, Niemi M. Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism. Clin Pharmacol Ther 2008; 84: 488-496.
-
(2008)
Clin Pharmacol Ther
, vol.84
, pp. 488-496
-
-
Kalliokoski, A.1
Backman, J.T.2
Kurkinen, K.J.3
Neuvonen, P.J.4
Niemi, M.5
-
8
-
-
33644908781
-
Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status
-
DOI 10.1111/j.1365-2125.2005.02556.x
-
Uno T, Shimizu M, Yasui-Furukori N, Sugawara K, Tateishi T. Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status. Br J Clin Pharmacol 2006; 61: 309-314. (Pubitemid 43382630)
-
(2006)
British Journal of Clinical Pharmacology
, vol.61
, Issue.3
, pp. 309-314
-
-
Uno, T.1
Shimizu, M.2
Yasui-Furukori, N.3
Sugawara, K.4
Tateishi, T.5
-
9
-
-
55149095948
-
Pharmacokinetic interaction of flecainide and paroxetine in relation to the CYP2D6*10 allele in healthy Korean subjects
-
Lim KS, Cho JY, Jang IJ, Kim BH, Kim J, Jeon JY et al. Pharmacokinetic interaction of flecainide and paroxetine in relation to the CYP2D6*10 allele in healthy Korean subjects. Br J Clin Pharmacol 2008; 66: 660-666.
-
(2008)
Br J Clin Pharmacol
, vol.66
, pp. 660-666
-
-
Lim, K.S.1
Cho, J.Y.2
Jang, I.J.3
Kim, B.H.4
Kim, J.5
Jeon, J.Y.6
-
10
-
-
39449122141
-
The effect of herbal medicine baicalin on pharmacokinetics of rosuvastatin, substrate of organic anion-transporting polypeptide 1B1
-
DOI 10.1038/sj.clpt.6100318, PII 6100318
-
Fan L, Zhang W, Guo D, Tan ZR, Xu P, Li Q et al. The effect of herbal medicine baicalin on pharmacokinetics of rosuvastatin, substrate of organic anion-transporting polypeptide 1B1. Clin Pharmacol Ther 2008; 83: 471-476. (Pubitemid 351272636)
-
(2008)
Clinical Pharmacology and Therapeutics
, vol.83
, Issue.3
, pp. 471-476
-
-
Fan, L.1
Zhang, W.2
Guo, D.3
Tan, Z.-R.4
Xu, P.5
Li, Q.6
Liu, Y.-Z.7
Zhang, L.8
He, T.-Y.9
Hu, D.-L.10
Wang, D.11
Zhou, H.-H.12
-
11
-
-
70149105801
-
CYP3A5*1/*3 genotype influences the blood concentration of tacrolimus in response to metabolic inhibition by ketoconazole
-
Chandel N, Aggarwal PK, Minz M, Sakhuja V, Kohli KK, Jha V. CYP3A5*1/*3 genotype influences the blood concentration of tacrolimus in response to metabolic inhibition by ketoconazole. Pharmacogenet Genomics 2009; 19: 458-463.
-
(2009)
Pharmacogenet Genomics
, vol.19
, pp. 458-463
-
-
Chandel, N.1
Aggarwal, P.K.2
Minz, M.3
Sakhuja, V.4
Kohli, K.K.5
Jha, V.6
-
12
-
-
6344233227
-
Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes
-
DOI 10.1177/0091270004269015
-
Yasui-Furukori N, Saito M, Uno T, Takahata T, Sugawara K, Tateishi T. Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes. J Clin Pharmacol 2004; 44: 1223-1229. (Pubitemid 39391480)
-
(2004)
Journal of Clinical Pharmacology
, vol.44
, Issue.11
, pp. 1223-1229
-
-
Yasui-Furukori, N.1
Saito, M.2
Uno, T.3
Takahata, T.4
Sugawara, K.5
Tateishi, T.6
-
13
-
-
21744458482
-
Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine
-
DOI 10.1111/j.1365-2125.2005.02381.x
-
Miura M, Tada H, Yasui-Furukori N, Uno T, Sugawara K, Tateishi T et al. Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine. Br J Clin Pharmacol 2005; 60: 61-68. (Pubitemid 40942782)
-
(2005)
British Journal of Clinical Pharmacology
, vol.60
, Issue.1
, pp. 61-68
-
-
Miura, M.1
Tada, H.2
Yasui-Furukori, N.3
Uno, T.4
Sugawara, K.5
Tateishi, T.6
Suzuki, T.7
-
14
-
-
1942423665
-
Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes
-
DOI 10.1111/j.1365-2125.2003.02047.x
-
Yasui-Furukori N, Takahata T, Nakagami T, Yoshiya G, Inoue Y, Kaneko S et al. Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. Br J Clin Pharmacol 2004; 57: 487-494. (Pubitemid 38519654)
-
(2004)
British Journal of Clinical Pharmacology
, vol.57
, Issue.4
, pp. 487-494
-
-
Yasui-Furukori, N.1
Takahata, T.2
Nakagami, T.3
Yoshiya, G.4
Inoue, Y.5
Kaneko, S.6
Tateishi, T.7
-
15
-
-
0027167470
-
Inhibition by paroxetine and desipramine metabolism in extensive but not in poor metabolizers of sparteine
-
DOI 10.1007/BF00316471
-
Brosen K, Hansen JG, Nielsen KK, Sindrup SH, Gram LF. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol 1993; 44: 349-355. (Pubitemid 23153452)
-
(1993)
European Journal of Clinical Pharmacology
, vol.44
, Issue.4
, pp. 349-355
-
-
Brosen, K.1
Hansen, J.G.2
Nielsen, K.K.3
Sindrup, S.H.4
Gram, L.F.5
-
16
-
-
0032847231
-
Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans
-
Lessard E, Yessine MA, Hamelin BA, O'Hara G, LeBlanc J, Turgeon J. Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. Pharmacogenetics 1999; 9: 435-443. (Pubitemid 29419562)
-
(1999)
Pharmacogenetics
, vol.9
, Issue.4
, pp. 435-443
-
-
Lessard, E.1
Yessine, M.-A.2
Hamelin, B.A.3
O'Hara, G.4
LeBlanc, J.5
Turgeon, J.6
-
17
-
-
0035217180
-
The genetic determinants of the CYP3A5 polymorphism
-
DOI 10.1097/00008571-200112000-00005
-
Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001; 11: 773-779. (Pubitemid 33151512)
-
(2001)
Pharmacogenetics
, vol.11
, Issue.9
, pp. 773-779
-
-
Hustert, E.1
Haberl, M.2
Burk, O.3
Wolbold, R.4
He, Y.-Q.5
Klein, K.6
Nuessler, A.C.7
Neuhaus, P.8
Klattig, J.9
Eiselt, R.10
Koch, I.11
Zibat, A.12
Brockmoller, J.13
Halpert, J.R.14
Zanger, U.M.15
Wojnowski, L.16
-
18
-
-
42749089907
-
Rapid and simultaneous determination of tacrolimus (FK506) and diltiazem in human whole blood by liquid chromatography-tandem mass spectrometry: Application to a clinical drug-drug interaction study
-
Li JL, Wang XD, Wang CX, Fu Q, Liu LS, Huang M et al. Rapid and simultaneous determination of tacrolimus (FK506) and diltiazem in human whole blood by liquid chromatography-tandem mass spectrometry: application to a clinical drug-drug interaction study. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 867: 111-118.
-
(2008)
J Chromatogr B Analyt Technol Biomed Life Sci
, vol.867
, pp. 111-118
-
-
Li, J.L.1
Wang, X.D.2
Wang, C.X.3
Fu, Q.4
Liu, L.S.5
Huang, M.6
-
19
-
-
0025779048
-
An efficient and simple method of DNA extraction from whole blood and cell lines to identify infectious agents
-
Loparev VN, Cartas MA, Monken CE, Velpandi A, Srinivasan A. An efficient and simple method of DNA extraction from whole blood and cell lines to identify infectious agents. J Virol Methods 1991; 34: 105-112.
-
(1991)
J Virol Methods
, vol.34
, pp. 105-112
-
-
Loparev, V.N.1
Cartas, M.A.2
Monken, C.E.3
Velpandi, A.4
Srinivasan, A.5
-
20
-
-
60549093838
-
Effect of genetic polymorphisms of CYP3A5 and MDR1 on cyclosporine concentration during the early stage after renal transplantation in Chinese patients co-treated with diltiazem
-
Wang Y, Wang C, Li J, Wang X, Zhu G, Chen X et al. Effect of genetic polymorphisms of CYP3A5 and MDR1 on cyclosporine concentration during the early stage after renal transplantation in Chinese patients co-treated with diltiazem. Eur J Clin Pharmacol 2009; 65: 239-247.
-
(2009)
Eur J Clin Pharmacol
, vol.65
, pp. 239-247
-
-
Wang, Y.1
Wang, C.2
Li, J.3
Wang, X.4
Zhu, G.5
Chen, X.6
-
21
-
-
33846632909
-
CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients
-
DOI 10.1038/sj.clpt.6100039, PII 6100039
-
Renders L, Frisman M, Ufer M, Mosyagin I, Haenisch S, Ott U et al. CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. Clin Pharmacol Ther 2007; 81: 228-234. (Pubitemid 46174820)
-
(2007)
Clinical Pharmacology and Therapeutics
, vol.81
, Issue.2
, pp. 228-234
-
-
Renders, L.1
Frisman, M.2
Ufer, M.3
Mosyagin, I.4
Haenisch, S.5
Ott, U.6
Caliebe, A.7
Dechant, M.8
Braun, F.9
Kunzendorf, U.10
Cascorbi, I.11
-
22
-
-
12144286933
-
The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients
-
DOI 10.1097/00008571-200403000-00002
-
Haufroid V, Mourad M, Van Kerckhove V, Wawrzyniak J, De Meyer M, Eddour DC et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 2004; 14: 147-154. (Pubitemid 38373108)
-
(2004)
Pharmacogenetics
, vol.14
, Issue.3
, pp. 147-154
-
-
Haufroid, V.1
Mourad, M.2
Van Kerckhove, V.3
Wawrzyniak, J.4
De Meyer, M.5
Eddour, D.C.6
Malaise, J.7
Lison, D.8
Squifflet, J.-P.9
Wallemacq, P.10
-
23
-
-
0041831261
-
Genetic polymorphisms of the CΥP3A4, CΥP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus
-
DOI 10.1016/S0009-9236(03)00168-1
-
Hesselink DA, Van Schaik RH, Van der Heiden IP, Van der Werf M, Gregoor PJ, Lindemans J et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74: 245-254. (Pubitemid 37083100)
-
(2003)
Clinical Pharmacology and Therapeutics
, vol.74
, Issue.3
, pp. 245-254
-
-
Hesselink, D.A.1
Van Schaik, R.H.N.2
Van Der Heiden, I.P.3
Van Der Werf, M.4
Smak Gregoor, P.J.H.5
Lindemans, J.6
Weimar, W.7
Van Gelder, T.8
-
24
-
-
33749984168
-
CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: Guidelines from an experimental study
-
DOI 10.1111/j.1600-6143.2006.01518.x
-
Haufroid V, Wallemacq P, VanKerckhove V, Elens L, De Meyer M, Eddour DC et al. CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study. Am J Transplant 2006; 6: 2706-2713. (Pubitemid 44571691)
-
(2006)
American Journal of Transplantation
, vol.6
, Issue.11
, pp. 2706-2713
-
-
Haufroid, V.1
Wallemacq, P.2
VanKerckhove, V.3
Elens, L.4
De Meyer, M.5
Eddour, D.C.6
Malaise, J.7
Lison, D.8
Mourad, M.9
-
25
-
-
45449099489
-
Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients
-
DOI 10.1016/j.transproceed.2008.04.010, PII S0041134508004284
-
Loh PT, Lou HX, Zhao Y, Chin YM, Vathsala A. Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients. Transplant Proc 2008; 40: 1690-1695. (Pubitemid 351853194)
-
(2008)
Transplantation Proceedings
, vol.40
, Issue.5
, pp. 1690-1695
-
-
Loh, P.T.1
Lou, H.X.2
Zhao, Y.3
Chin, Y.M.4
Vathsala, A.5
-
27
-
-
0026681546
-
Functional and morphological changes in rat kidney induced by FK506 and its reversal by various vasodilators
-
Kumano K, Endo T, Koshiba K. [Functional and morphological changes in rat kidney induced by FK506 and its reversal by various vasodilators]. Nippon Hinyokika Gakkai Zasshi 1992; 83: 650-657.
-
(1992)
Nippon Hinyokika Gakkai Zasshi
, vol.83
, pp. 650-657
-
-
Kumano, K.1
Endo, T.2
Koshiba, K.3
-
28
-
-
0028916159
-
Particular ability of cytochromes P450 3A to form inhibitory P450-iron-metabolite complexes upon metabolic oxidation of aminodrugs
-
Bensoussan C, Delaforge M, Mansuy D. Particular ability of cytochromes P450 3A to form inhibitory P450-iron-metabolite complexes upon metabolic oxidation of aminodrugs. Biochem Pharmacol 1995; 49: 591-602.
-
(1995)
Biochem Pharmacol
, vol.49
, pp. 591-602
-
-
Bensoussan, C.1
Delaforge, M.2
Mansuy, D.3
-
29
-
-
4644263308
-
CYP3A5 contributes significantly to CYP3A-mediated drug oxidations in liver microsomes from Japanese subjects
-
Yamaori S, Yamazaki H, Iwano S, Kiyotani K, Matsumura K, Honda G et al. CYP3A5 contributes significantly to CYP3A-mediated drug oxidations in liver microsomes from Japanese subjects. Drug Metab Pharmacokinet 2004; 19: 120-129.
-
(2004)
Drug Metab Pharmacokinet
, vol.19
, pp. 120-129
-
-
Yamaori, S.1
Yamazaki, H.2
Iwano, S.3
Kiyotani, K.4
Matsumura, K.5
Honda, G.6
-
30
-
-
31344466713
-
Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients
-
Uesugi M, Masuda S, Katsura T, Oike F, Takada Y, Inui K. Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in livingdonor liver transplant recipients. Pharmacogenet Genomics 2006; 16: 119-127. (Pubitemid 43145680)
-
(2006)
Pharmacogenetics and Genomics
, vol.16
, Issue.2
, pp. 119-127
-
-
Uesugi, M.1
Masuda, S.2
Katsura, T.3
Oike, F.4
Takada, Y.5
Inui, K.-I.6
-
31
-
-
0035071598
-
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression
-
DOI 10.1038/86882
-
Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383-391. (Pubitemid 32268418)
-
(2001)
Nature Genetics
, vol.27
, Issue.4
, pp. 383-391
-
-
Kuehl, P.1
Zhang, J.2
Lin, Y.3
Lamba, J.4
Assem, M.5
Schuetz, J.6
Watkins, P.B.7
Daly, A.8
Wrighton, S.A.9
Hall, S.D.10
Maurel, P.11
Relling, M.12
Brimer, C.13
Yasuda, K.14
Venkataramanan, R.15
Strom, S.16
Thummel, K.17
Boguski, M.S.18
Schuetz, E.19
-
32
-
-
34548695887
-
Expression of CYP3A isoforms and P-glycoprotein in human stomach, jejunum and ileum
-
DOI 10.1111/j.1440-1681.2007.04691.x
-
Canaparo R, Finnstrom N, Serpe L, Nordmark A, Muntoni E, Eandi M et al. Expression of CYP3A isoforms and P-glycoprotein in human stomach, jejunum and ileum. Clin Exp Pharmacol Physiol 2007; 34: 1138-1144. (Pubitemid 47416351)
-
(2007)
Clinical and Experimental Pharmacology and Physiology
, vol.34
, Issue.11
, pp. 1138-1144
-
-
Canaparo, R.1
Finnstrom, N.2
Serpe, L.3
Nordmark, A.4
Muntoni, E.5
Eandi, M.6
Rane, A.7
Zara, G.P.8
-
33
-
-
1542376174
-
Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: A comparative analysis in paired tissue specimens
-
DOI 10.1016/j.clpt.2003.10.008, PII S0009923603007288
-
Von Richter O, Burk O, Fromm MF, Thon KP, Eichelbaum M, Kivisto KT. Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens. Clin Pharmacol Ther 2004; 75: 172-183. (Pubitemid 38314866)
-
(2004)
Clinical Pharmacology and Therapeutics
, vol.75
, Issue.3
, pp. 172-183
-
-
Von Richter, O.1
Burk, O.2
Fromm, M.F.3
Thon, K.P.4
Eichelbaum, M.5
Kivisto, K.T.6
-
34
-
-
0038000046
-
The nuclear pregnane X receptor regulates xenobiotic detoxification
-
Kliewer SA. The nuclear pregnane X receptor regulates xenobiotic detoxification. J Nutr 2003; 133: 2444S-2447S. (Pubitemid 36828852)
-
(2003)
Journal of Nutrition
, vol.133
, Issue.7 SUPPL.
-
-
Kliewer, S.A.1
-
35
-
-
0034785945
-
The human pregnane X receptor: Genomic structure and identification and functional characterization of natural allelic variants
-
DOI 10.1097/00008571-200110000-00003
-
Zhang J, Kuehl P, Green ED, Touchman JW, Watkins PB, Daly A et al. The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics 2001; 11: 555-572. (Pubitemid 32953582)
-
(2001)
Pharmacogenetics
, vol.11
, Issue.7
, pp. 555-572
-
-
Zhang, J.1
Kuehl, P.2
Green, E.D.3
Touchman, J.W.4
Watkins, P.B.5
Daly, A.6
Hall, S.D.7
Maurel, P.8
Relling, M.9
Brimer, C.10
Yasuda, K.11
Wrighton, S.A.12
Hancock, M.13
Kim, R.B.14
Strom, S.15
Thummel, K.16
Russell, C.G.17
Hudson Jr., J.R.18
Schuetz, E.G.19
Boguski, M.S.20
more..
-
36
-
-
37549010733
-
Novel single nucleotide polymorphisms in the promoter and intron 1 of human pregnane X receptor/NR1I2 and their association with CYP3A4 expression
-
Lamba J, Lamba V, Strom S, Venkataramanan R, Schuetz E. Novel single nucleotide polymorphisms in the promoter and intron 1 of human pregnane X receptor/NR1I2 and their association with CYP3A4 expression. Drug Metab Dispos 2008; 36: 169-181.
-
(2008)
Drug Metab Dispos
, vol.36
, pp. 169-181
-
-
Lamba, J.1
Lamba, V.2
Strom, S.3
Venkataramanan, R.4
Schuetz, E.5
-
37
-
-
0028917496
-
Pharmacokinetics of tacrolimus in liver transplant patients
-
Jusko WJ, Piekoszewski W, Klintmalm GB, Shaefer MS, Hebert MF, Piergies AA et al. Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther 1995; 57: 281-290.
-
(1995)
Clin Pharmacol Ther
, vol.57
, pp. 281-290
-
-
Jusko, W.J.1
Piekoszewski, W.2
Klintmalm, G.B.3
Shaefer, M.S.4
Hebert, M.F.5
Piergies, A.A.6
|